Key result
V10 ≥24.8% and Stage IV linked to ~6.5-fold higher risk of symptomatic radiation pneumonitis.
Why the study?
Clinical and dosimetric factors predicting radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation were not well defined.
What are the clinical and dosimetric predictive factors for symptomatic radiation pneumonitis in esophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation?
Cohort (n=125)
What are the clinical and dosimetric predictive factors for symptomatic radiation pneumonitis in esophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation?
Stage IV disease and dosimetric factors (such as V10 ≥ 24.8%) independently predict symptomatic radiation pneumonitis in esophageal cancer patients receiving chemoradiotherapy without prophylactic nodal irradiation.
OBJECTIVE: The objective of this study was to identify clinical and dosimetric factors for the development of radiation pneumonitis (RP) among patients with oesophageal cancer treated with three-dimensional radiotherapy without prophylactic nodal irradiation. METHODS: 125 patients with oesophageal cancer had undergone dose-volume histogram (DVH) metrics and received chemoradiotherapy (CRT). Several clinical and dosimetric factors with regard to the lung were evaluated as predictive factors for the development of symptomatic RP. RESULTS: 26 patients (20.8%) developed symptomatic RP classified as greater than or equal to Grade 2. By univariate analysis, body weight loss, tumour length, Stage IV, response to treatment and all DVH parameters proved to be significant factors for the development of RP (p < 0.05). By multivariate analysis, Stage IV and all dosimetric factors were independent predictive factors for the development of symptomatic RP (p < 0.05). Recursive partitioning analysis indicated that V10 values of 24.8% or more and Stage IV were associated with higher development of RP (odds ratio 6.53). CONCLUSIONS: Our study demonstrated that severe RP was also developed in patients treated with the minimal radiation field. Stage IV and the dosimetric factors were identified as independent predictive factors for symptomatic RP in oesophageal cancer patients treated with CRT without prophylactic nodal irradiation.
No takes yet. Share an insight, caveat, or question.
Nomura et al. (2012) conducted a cohort in oesophageal cancer (n=125). V10 values ≥ 24.8% and Stage IV vs. V10 < 24.8% and/or lower stage was evaluated on symptomatic radiation pneumonitis ≥ Grade 2 (OR 6.53, p=< 0.05). V10 values of 24.8% or more and Stage IV were associated with a higher risk of developing symptomatic radiation pneumonitis (OR 6.53).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: